Propafenone

Indications
 Oral
Supraventricular and ventricular arrhythmias
Adult: Doses should be started under close monitoring of ECG and BP. For immediate-release tablet: Usual initial doses: 150 mg tid, may increase at intervals of 3-4 days up to 300 mg tid. Dose reduction is recommended in patients weighing <70 kg. For extended-release capsule: Initial doses: 225 mg every 12 hr; may increase dose at intervals of at least 5 days, up to 325-425 mg every 12 hr
Elderly: Dose reduction is recommended.
Hepatic impairment: Dose reduction is recommended.

Special Populations: Reduce dose in elderly, patients weighing <70 kg and in those with hepatic impairment.
Contraindications
 Uncontrolled heart failure, marked hypotension, severe bradycardia and heart block, conduction abnormalities, cardiogenic shock, myasthenia gravis.
Warnings / Precautions
 Severe pulmonary obstructive diseases, CHF, cardiac pacemaker, impaired renal/hepatic function, pregnancy, lactation, elderly. Correct electrolyte disturbances before starting treatment. May worsen heart failure in patients with preexisting organic heart disease. May worsen or cause new severe ventricular arrhythmias e.g. ventricular tachycardia or fibrillation. May aggravate electrically induced ventricular tachycardia in some patients.
Adverse Reactions
 Dizziness, headache, visual disturbances, vertigo, dry mouth, GI disturbances, alteration in taste, allergic skin rashes, leucopenia, bradycardia and bitter or metallic taste.
Potentially Fatal: SA/AV or intraventricular blocks. Severe hypotension, especially in elderly.
Drug Interactions
 Reduced plasma levels when used with enzyme inducers e.g. rifampicin. Increased plasma levels when used with enzyme inhibitors e.g. cimetidine, fluoxetine, quinidine and HIV protease inhibitors. Absorption is reduced by orlistat. Increased risk of arrhythmias when used with antiarrhythmics/arrhythmogenic drugs. Increased serum levels of theophylline, metoprolol and propanolol when used concurrently. Increased risk of bradycardia and heart block when used with β-blockers.
Potentially Fatal: Increased digoxin plasma levels. Potentiates anticoagulant effects of warfarin.
See Below for More propafenone Drug Interactions
Mechanism of Actions
 Propafenone is a class 1C antiarrhythmic drug with local anaesthetic effects, and a direct stabilising action on myocardial membranes. The electrophysiological effect manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity.
Absorption: Readily and well-absorbed from the GI tract (oral).
Distribution: Crosses the placenta and appears in breast milk. Protein-binding: 95%.
Metabolism: Hepatic; by the cytochrome P450 isoenzyme CYP2D6, glucuronidation.
Excretion: Urine and faeces (as metabolites); Elimination half-life: 2-10 hr (fast metabolisers); 10-32 hr (slow metabolisers).
Administration
 Should be taken with food. (Take after meals. Swallow whole, do not chew/crush.)
Storage Conditions
 Oral: Store at 25°C.
ATC Classification
 C01BC03 - propafenone ; Belongs to class Ic antiarrhythmics.
Storage
 Oral: Store at 25°C.
Available As
  • Propafenone 150 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Propafenone


    Propafenone Containing Brands

    We are Developing Our database, More results coming soon.

    Propafenone is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Propafenone

    We are Developing Our database, More results coming soon.